PHA-739358 for the Treatment of Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03836053

Relapsed and/or Refractory Multiple Myeloma

TERMINATED PHASE1

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

NCT03379584

Multiple Myeloma

TERMINATED PHASE1

Myeloma-Developing Regimens Using Genomics (MyDRUG)

NCT03732703

Relapsed Refractory Multiple Myeloma

COMPLETED PHASE1/PHASE2

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916

Relapsed or Refractory Multiple Myeloma

COMPLETED PHASE1

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

NCT07312188

Relapsed or Refractory Multiple Myeloma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

PHA-739358

Intervention Type DRUG

Weekly IV infusion for 3 consecutive weeks in a 4-week cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PHA-739358

Weekly IV infusion for 3 consecutive weeks in a 4-week cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* active multiple myeloma progressing after at least 2 prior lines of treatment
* measurable disease
* t(4;14) translocation
* life expectancy of at least 3 months

Exclusion Criteria

* uncontrolled hypertension
* myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
* pregnancy or breast feeding
* active infections, including HIV

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No